Exercise of Warrants and Issue of Equity

Summary by AI BETAClose X

Hemogenyx Pharmaceuticals plc has announced the exercise of warrants, resulting in the issuance of 50,841 new ordinary shares and raising £118,632 for the company. These new shares, which will rank pari passu with existing ordinary shares, are expected to be admitted to trading on the LSE's main market around February 27, 2026. Following this admission, the total number of issued shares and voting rights in the company will be 6,425,429.

Disclaimer*

UK 100

Latest directors dealings